|
Self-reported sleep disturbance and survival in myelodysplastic syndromes
|
Mar 2017
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
|
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics
|
Aug 2012
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
|
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
|
Jan 2017
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.
|
Mar 2012
|
Leuk Res
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
|
Jul 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes
|
Jun 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)
|
Apr 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
